M. Dolores Delgado

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9422898/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	A novel role of MNT as a negative regulator of REL and the NF- $\hat{I}^{e}B$ pathway. Oncogenesis, 2021, 10, 5.	4.9	1
2	The MNT transcription factor autoregulates its expression and supports proliferation in MYC-associated factor X (MAX)-deficient cells. Journal of Biological Chemistry, 2020, 295, 2001-2017.	3.4	10
3	Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells. Scientific Reports, 2019, 9, 16495.	3.3	27
4	MYC Oncogene Contributions to Release of Cell Cycle Brakes. Genes, 2019, 10, 244.	2.4	136
5	Myc and cell cycle control. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2015, 1849, 506-516.	1.9	538
6	The epigenetic regulator CTCF modulates BCL6 in lymphoma. Oncoscience, 2015, 2, 783-784.	2.2	2
7	A novel mutation in ADAMTS13 of a child with Upshaw-Schulman Syndrome. Thrombosis and Haemostasis, 2014, 112, 1065-1068.	3.4	3
8	MYC oncogene in myeloid neoplasias. Clinical and Translational Oncology, 2013, 15, 87-94.	2.4	51
9	MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27KIP1. Oncogene, 2013, 32, 2239-2246.	5.9	54
10	The male germ cell gene regulator CTCFL is functionally different from CTCF and binds CTCF-like consensus sites in a nucleosome composition-dependent manner. Epigenetics and Chromatin, 2012, 5, 8.	3.9	80
11	Transcription Factors Sp1 and p73 Control the Expression of the Proapoptotic Protein NOXA in the Response of Testicular Embryonal Carcinoma Cells to Cisplatin. Journal of Biological Chemistry, 2012, 287, 26495-26505.	3.4	41
12	p21 as a Transcriptional Co-Repressor of S-Phase and Mitotic Control Genes. PLoS ONE, 2012, 7, e37759.	2.5	42
13	A Cell Cycle Role for the Epigenetic Factor CTCF-L/BORIS. PLoS ONE, 2012, 7, e39371.	2.5	37
14	Nuclear Targeting of a Bacterial Integrase That Mediates Site-Specific Recombination between Bacterial and Human Target Sequences. Applied and Environmental Microbiology, 2011, 77, 201-210.	3.1	13
15	MYC in Chronic Myeloid Leukemia: Induction of Aberrant DNA Synthesis and Association with Poor Response to Imatinib. Molecular Cancer Research, 2011, 9, 564-576.	3.4	54
16	CTCF regulates the local epigenetic state of ribosomal DNA repeats. Epigenetics and Chromatin, 2010, 3, 19.	3.9	80
17	Myc Roles in Hematopoiesis and Leukemia. Genes and Cancer, 2010, 1, 605-616.	1.9	217
18	p21Cip1 Confers resistance to imatinib in human chronic myeloid leukemia cells. Cancer Letters, 2010, 292, 133-139.	7.2	20

#	Article	IF	CITATIONS
19	Inhibition of cell differentiation: A critical mechanism for MYC-mediated carcinogenesis?. Cell Cycle, 2009, 8, 1148-1157.	2.6	54
20	HCT116 cells deficient in p21Waf1 are hypersensitive to tyrosine kinase inhibitors and adriamycin through a mechanism unrelated to p21 and dependent on p53. DNA Repair, 2009, 8, 390-399.	2.8	17
21	PU.1 expression is restored upon treatment of chronic myeloid leukemia patients. Cancer Letters, 2008, 270, 328-336.	7.2	18
22	Myc Inhibits p27-Induced Erythroid Differentiation of Leukemia Cells by Repressing Erythroid Master Genes without Reversing p27-Mediated Cell Cycle Arrest. Molecular and Cellular Biology, 2008, 28, 7286-7295.	2.3	53
23	Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors. Nucleic Acids Research, 2007, 35, 7372-7388.	14.5	94
24	Dequalinium induces cell death in human leukemia cells by early mitochondrial alterations which enhance ROS production. Leukemia Research, 2007, 31, 969-978.	0.8	50
25	Gene expression regulation and cancer. Clinical and Translational Oncology, 2006, 8, 780-787.	2.4	24
26	The Potential of BORIS Detected in the Leukocytes of Breast Cancer Patients as an Early Marker of Tumorigenesis. Clinical Cancer Research, 2006, 12, 5978-5986.	7.0	41
27	Targeting of CTCF to the nucleolus inhibits nucleolar transcription through a poly(ADP-ribosyl)ation-dependent mechanism. Journal of Cell Science, 2006, 119, 1746-1759.	2.0	75
28	Effects of the antitumoural dequalinium on NB4 and K562 human leukemia cell lines. Leukemia Research, 2005, 29, 1201-1211.	0.8	50
29	CTCF Regulates Growth and Erythroid Differentiation of Human Myeloid Leukemia Cells. Journal of Biological Chemistry, 2005, 280, 28152-28161.	3.4	76
30	p21Cip1 and p27Kip1 Induce Distinct Cell Cycle Effects and Differentiation Programs in Myeloid Leukemia Cells. Journal of Biological Chemistry, 2005, 280, 18120-18129.	3.4	81
31	Levels of Gli3 repressor correlate withBmp4 expression and apoptosis during limb development. Developmental Dynamics, 2004, 231, 148-160.	1.8	60
32	C-myc expression in cell lines derived from chronic myeloid leukemia. Haematologica, 2004, 89, 241-3.	3.5	15
33	Amifostine impairs p53-mediated apoptosis of human myeloid leukemia cells. Molecular Cancer Therapeutics, 2003, 2, 893-900.	4.1	17
34	Identification of a Candidate Tumor-Suppressor Gene Specifically Activated during Ras-Induced Senescence. Experimental Cell Research, 2002, 273, 127-137.	2.6	58
35	Functional Phosphorylation Sites in the C-Terminal Region of the Multivalent Multifunctional Transcriptional Factor CTCF. Molecular and Cellular Biology, 2001, 21, 2221-2234.	2.3	89
36	c-Myc inhibits CD11a and CD11c leukocyte integrin promoters. European Journal of Immunology, 2000, 30, 2465-2471.	2.9	10

M. DOLORES DELGADO

#	ARTICLE	IF	CITATIONS
37	H-, K- and N-Ras inhibit myeloid leukemia cell proliferation by a p21WAF1-dependent mechanism. Oncogene, 2000, 19, 783-790.	5.9	53
38	c-Myc antagonizes the effect of p53 on apoptosis and p21WAF1 transactivation in K562 leukemia cells. Oncogene, 2000, 19, 2194-2204.	5.9	58
39	Simultaneous occurrence of follicular lymphoma in two monozygotic twins. British Journal of Haematology, 1999, 107, 461-462.	2.5	4
40	Differential expression and phosphorylation of CTCF, a c-myctranscriptional regulator, during differentiation of human myeloid cells. FEBS Letters, 1999, 444, 5-10.	2.8	31
41	Apoptosis and Mitotic Arrest Are Two Independent Effects of the Protein Phosphatases Inhibitor Okadaic Acid in K562 Leukemia Cells. Biochemical and Biophysical Research Communications, 1999, 260, 256-264.	2.1	42
42	Spi-1/PU.1 Proto-oncogene Induces Opposite Effects on Monocytic and Erythroid Differentiation of K562 Cells. Biochemical and Biophysical Research Communications, 1998, 252, 383-391.	2.1	19
43	Interferon Induces Up-regulation of Spi-1/PU.1 in Human Leukemia K562 Cells. Biochemical and Biophysical Research Communications, 1997, 240, 862-868.	2.1	10
44	Max and inhibitory c-Myc mutants induce erythroid differentiation and resistance to apoptosis in human myeloid leukemia cells. Oncogene, 1997, 14, 1315-1327.	5.9	51
45	Down Regulation of C-MYC and MAX Genes Is Associated to Inhibition of Protein Phosphatase 2A in K562 Human Leukemia Cells. Biochemical and Biophysical Research Communications, 1995, 215, 889-895.	2.1	18
46	Induction of apolipoprotein E expression during erythroid differentiation of human K562 leukemia cells. Leukemia Research, 1993, 17, 771-776.	0.8	3
47	MYC as therapeutic target in leukemia and lymphoma. Blood and Lymphatic Cancer: Targets and Therapy, 0, , 75,	2.7	2